#United States #Class Action #Radnor #SEC Fraud #Soleno Therapeutics

Attention Soleno Therapeutics Investors

If you purchased common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025, and November 4, 2025, there is crucial information you need to know regarding a securities fraud class action lawsuit. This legal action has been initiated against Soleno Therapeutics concerning numerous allegations related to the company's operations and the safety of its products.

Background of the Lawsuit

On April 8, 2026, it was revealed that a litigation firm, Kessler Topaz Meltzer & Check, LLP, filed a lawsuit in the United States District Court for the Northern District of California. This lawsuit is on behalf of investors who claim to have been misled by significant misstatements and omissions from Soleno regarding its Phase 3 clinical trial program for its primary product, diazoxide choline extended-release tablets, known as DCCR.

Allegations Against Soleno Therapeutics

The lawsuit outlines allegations that the defendants made materially false and misleading statements about the business and operations of Soleno. Specifically, it is claimed that:
1. Safety Concerns: Soleno’s Phase 3 clinical trials for DCCR inadequately reported safety issues related to fluid retention in participants, posing risks that were not disclosed adequately.
2. Undisclosed Risks: Due to these safety concerns, DCCR was determined to have lower commercial viability than what had been represented by Soleno officials, leading to potential adverse events after its release.
3. Stock Performance and Market Reaction: Following a report by Scorpion Capital on August 15, 2025, which highlighted significant issues within Soleno's clinical trials, the company’s stock price plummeted over 26%. This was indicative of investor concern that escalated due to increased patient discontinuation rates and diminished market confidence in the product.

Important Dates and Actions

Investors have a deadline of May 5, 2026, to seek to be designated as a lead plaintiff in this class action. A lead plaintiff acts on behalf of all class members, guiding the litigation process. Investors are advised to contact Kessler Topaz Meltzer & Check to discuss legal options, especially if they've incurred losses due to their investments in Soleno.

What Can Affected Investors Do?

• - Contact an Attorney: Investors can reach out to Kessler Topaz Meltzer & Check for a free evaluation of their case, with no upfront fees, as the firm operates on a contingency fee basis.
• - Consider Lead Plaintiff Status: Filing to take on the role of lead plaintiff can maximize your chance of recovery, depending on the outcome of the case.
• - Keep Informed: Staying up to date with the lawsuit developments is crucial; potential outcomes may influence future investments and strategies.

For your legal rights and to discuss details about representing in this case, you can contact attorney Jonathan Naji at Kessler Topaz Meltzer & Check, LLP at (484) 270-1453, or visit their website for further information.

Conclusion

With a looming deadline for action and the significant implications of the lawsuit for current investors, staying informed and proactive is essential for those affected by Soleno Therapeutics’ recent challenges. Investors are encouraged to explore all available options to ensure their interests are adequately protected in the wake of this developing situation.